FCGRT and myasthenia gravis: As B cells (including antibody secreting cells) and immunoglobulins have been shown to play multiple important roles in MG pathogenesis (6, 29), we have evaluated the efficacy of povetacicept in modulating clinical manifestations in the mouse EAMG model in the studies described herein, by comparing povetacicept treatment to (i) telitacicept, (ii) anti-CD20 (B cell depleting) mAb, (iii) efgartigimod (FcRn blocker), (iv) Fc control, and (v) PBS (vehicle), administered in the chronic EAMG phase (after the second AChR/IFA boost).